{"id":5552,"date":"2025-04-25T11:09:40","date_gmt":"2025-04-25T03:09:40","guid":{"rendered":"https:\/\/wisdp.org\/wp\/?p=5552"},"modified":"2025-04-28T17:03:57","modified_gmt":"2025-04-28T09:03:57","slug":"rsdc-hutchmed","status":"publish","type":"post","link":"https:\/\/wisdp.org\/wp\/2025\/04\/25\/rsdc-hutchmed\/","title":{"rendered":"RSDC Introduction – HUTCHMED (China) Limited"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Recognised Sustainable Development Corporation
HUTCHMED (China) Limited<\/i>
Leading the Sustainable Healthcare - Pharmaceuticals & Biotechnology Industry<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

HUTCHMED (China) Limited was presented the Recognised Sustainable Development Corporation Certificate (No.: R10019) at the 2023 GBA Corporate Sustainability Awards, demonstrating its determination and potential in promoting sustainable development.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

HutchMed is an innovative biopharmaceutical company at the commercialisation stage, dedicated to the discovery, global development, and commercialisation of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.<\/span><\/p>

In 2023, three of its main innovative drugs\u2014FRUZAQLA\u00ae, Sulanda\u00ae (Surufatinib), and Orpathys\u00ae (Savolitinib)\u2014continued to be included in the National Reimbursement Drug List (NRDL).<\/span><\/p>

After receiving approval from China’s National Medical Products Administration, FRUZAQLA\u00ae and Sulanda\u00ae (Surufatinib) were also approved for sale in Macau, significantly enhancing the accessibility and affordability of innovative medicines for Chinese patients.<\/span><\/p>

\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

HutchMed is dedicated to driving transformation and integrating sustainable development concepts across all aspects of its operations to create long-term value for investors and stakeholders. In the past, they have introduced and implemented significant sustainability initiatives, including reassessing the importance of sustainability issues, establishing a series of sustainability goals for the group, and conducting climate-related risk assessments.<\/span><\/p>

HutchMed aims to work closely with various stakeholders to reduce its carbon footprint and become a more energy-efficient enterprise.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\ud83d\udce2<\/span>\u00a0Apply to become a RSDC, earn a trusted professional certification, and showcase your impact to all sectors of society!”\uff01<\/p>

\ud83d\udc49\ud83c\udffb Learn more\uff1ahttp:\/\/wisdp.org\/wp\/certification-csdc\/\u2028<\/p>

\u260e\ufe0f Enquire\uff1a2312 7696 \/ info@wisdp.org<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tJoin Us Now<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

HUTCHMED (China) Limited was presented the Recognised Sustainable Development Corporation Certificate (No.: R10019) at the 2023 GBA Corporate Sustainability Awards, demonstrating its determination and potential in promoting sustainable development.…Continue readingRSDC Introduction – HUTCHMED (China) Limited<\/span><\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":5615,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[6,7],"class_list":["post-5552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-corporatemember","tag-rsdc"],"_links":{"self":[{"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/posts\/5552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/comments?post=5552"}],"version-history":[{"count":71,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/posts\/5552\/revisions"}],"predecessor-version":[{"id":5662,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/posts\/5552\/revisions\/5662"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/media\/5615"}],"wp:attachment":[{"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/media?parent=5552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/categories?post=5552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wisdp.org\/wp\/wp-json\/wp\/v2\/tags?post=5552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}